Non-interventional (observational) study of application of the tamsulosin (Proflosin®) in patients with benign prostatic hyperplasia in routine clinical practice

The problem of therapy of benign prostatic hyperplasia has not lost its relevance today due to the high prevalence rate of this pathology
among the male population. The article provides the results of non-interventional (observational) study of application of the tamsulosin
(Proflosin®) drug or combined therapy with tamsulosin (Proflosin®) + Serenoa repens (Prostamol® Uno) of patients with benign prostatic hyperplasia in routine clinical practice. 1,000 practicing urology experts from 100 cities and towns of Russia took part in the study as well as 23 492 patients with the established diagnosis of benign prostatic hyperplasia, which were prescribed with tamsulosin (Proflosin®) monotherapy or combined therapy with tamsulosin (Proflosin®) + Serenoa repens (Prostamol® Uno) in conditions of outpatient clinical practice. As a result of the study, improvement of the life standard and subjective symptoms were stated with patients with the absence of significant side effects directly associated with intake of the drug studies.